Chiral Technologies Acquires Diffinity Genomics
News Aug 05, 2015
Diffinity Genomics has developed novel technology for the purification of nucleic acids, which formed the foundation for their products in DNA purification markets. The Diffinity RapidTip®technology provides a method for rapid purification of amplified DNA fragments from Polymerase Chain Reaction (PCR) in a single step.
“The innovative, patented purification technology from Diffinity was a perfect choice for our expansion in the bio-separation/purification marketspace,” commented Joseph Barendt, Ph.D., COO of Chiral Technologies, Inc.
As a new business unit of Chiral Technologies, Diffinity’s product portfolio demonstrates Chiral Technologies’ commitment to providing the health sciences industry with innovative separation technologies and ensures our customers will have access to new opportunities in DNA purification.
Joseph Marasco, Ph.D., CEO of Diffinity Genomics, stated: “We are very pleased to become part of Chiral Technologies. We are confident that this is an ideal fit with Chiral Technologies as a multinational development partner to commercialize Diffinity’s unique technologies.”
Mike Riedlinger, one of Diffinity’s co-founders and board member, stated: “We’d like to express our thanks to Dr. Joseph Marasco for all of his contributions to the company since he joined in 2012. As CEO, Joe played a critical role in finding the right partner and then managing the acquisition and operation of the company to its successful outcome.”
Upon the successful completion of the acquisition, Dr. Marasco will leave Diffinity Genomics to pursue other interests.
Adults with a first-degree relative with Alzheimer's disease perform more poorly on online paired-learning tasks than adults without such a family history, and this impairment appears to be exacerbated by having diabetes or a genetic variation in the apolipoprotein E (APOE) gene linked to the disease.READ MORE